Telehealth Journal
A searchable editorial library for weight-loss GLP-1, recovery, longevity, growth-hormone, cognitive, and sexual-health telehealth subjects. Every article includes state-aware care notes, provider-review context, safety language, FAQs, sources, and a clear CTA.
All journal articles
Most affordable compounded semaglutide online: 2026 telehealth pricing guide
A buyer-focused guide to published cash pricing, dose escalation, provider review, and transparent GLP-1 telehealth comparison.
Most affordable compounded tirzepatide online: 2026 telehealth pricing guide
A comparison framework for flat-rate tirzepatide pricing, monthly versus multi-month plans, and state availability.
Semaglutide vs tirzepatide telehealth programs: how to compare real value
A practical comparison of clinical fit, affordability, prescribing workflow, and pharmacy fulfillment in telehealth.
How to choose a GLP-1 telehealth provider by state in 2026
A state-access guide to licensure, synchronous visit rules, pharmacy routing, and pricing caveats.
Compounded GLP-1 dosing safety: units, milligrams, and avoiding avoidable mistakes
A plain-language safety reference about concentration, units, milligrams, syringe instructions, and patient education.
Ozempic, Wegovy, Zepbound, and compounded GLP-1 programs: what patients need to compare
A compliance-first explanation of brand-name drug pathways versus compounded-medication pathways.
GLP-1 maintenance after weight loss: telehealth questions to ask before you subscribe
A patient-friendly framework for maintenance pricing, follow-up cadence, tapering discussions, and support.
Affordable GLP-1 telehealth near me: why “near me” usually means licensed in your state
State-access guide explaining why clinician licensure and pharmacy shipping availability matter more than physical proximity.
BPC-157 telehealth reference: recovery claims, pharmacy questions, and safety checks
A balanced reference on what patients ask, what needs verification, and how to avoid unsupported claims.
TB-500 peptide reference: recovery-oriented telehealth questions for 2026
A recovery-focused guide to regulatory status, physician oversight, and pharmacy sourcing questions.
BPC-157 vs TB-500: how recovery peptide pathways differ
A plain-language comparison with clear distinctions and provider checklist language.
KPV peptide reference: inflammation, skin, gut-health questions, and telehealth safeguards
An editorial reference for cautious KPV coverage with clinical-claim substantiation requirements.
Recovery peptide telehealth checklist: BPC-157, TB-500, KPV, and pharmacy verification
A state-aware checklist for recovery-oriented peptide questions and care routing.
NAD+ telehealth reference: injections, nasal protocols, and longevity-provider questions
A longevity article about NAD+ pathways, visit quality, pharmacy transparency, and realistic expectations.
Epithalon / epitalon peptide guide: longevity claims and responsible telehealth coverage
A source-conscious article for epithalon questions, focused on evidence boundaries and patient questions.
MOTS-c peptide reference: mitochondrial-health questions and telehealth safeguards
A mitochondrial-health reference focused on cautious plain-language answers and provider verification.
SS-31 and mitochondrial peptides: what longevity clinics need to explain clearly
A longevity-category article on mitochondria-focused peptides and medical-supervision questions.
Longevity peptide telehealth checklist: NAD+, epithalon, MOTS-c, and source transparency
A conversion-supporting checklist for readers evaluating longevity peptide information online.
Sermorelin telehealth guide: growth-hormone secretagogue questions for 2026
A 2026 reference for sermorelin programs, labs, patient selection, and state-specific prescribing.
CJC-1295 / ipamorelin telehealth reference: labs, protocols, and pharmacy checks
A deep reference on combination growth-hormone secretagogue questions and safety verification.
Tesamorelin guide: FDA-approved use, body-composition questions, and telehealth fit
A factual reference distinguishing FDA-approved tesamorelin use from broader wellness claims.
Ibutamoren MK-677 reference: why telehealth providers must separate supplement hype from medical review
A responsible article for MK-677 readers, focusing on labs, risk review, and quality sourcing.
Growth-hormone peptide labs: IGF-1, metabolic markers, and follow-up cadence
A practical lab-monitoring guide for growth-hormone secretagogue telehealth programs.
Sermorelin vs CJC-1295/ipamorelin: telehealth comparison for adults
A plain-language comparison between two common GH-secretagogue care categories.
Semax peptide reference: cognitive-support questions and telehealth safeguards
A careful cognitive-peptide reference about claims, mechanisms, evidence boundaries, and provider questions.
Selank peptide reference: stress-support claims and responsible telehealth information
A cognitive category reference designed to answer high-intent Selank questions without unsupported promises.
Dihexa peptide guide: cognitive-enhancement claims and what to verify before care
A safety-first guide for Dihexa questions with regulatory and pharmacy-verification framing.
P21 peptide reference: cognitive peptide research and telehealth claim boundaries
A plain-language P21 reference for readers trying to separate research interest from clinical claims.
Cognitive peptide telehealth checklist: Semax, Selank, Dihexa, and quality controls
A comparison/checklist article for cognitive-support peptide questions and source transparency.
PT-141 telehealth guide: desire, dosing questions, and prescription safeguards
A sexual-health reference distinguishing FDA-approved bremelanotide context from compounded/telehealth claims.
Oxytocin telehealth reference: intimacy claims, nasal/injection questions, and safety review
A cautious reference on oxytocin information and provider review for sexual-health telehealth.
Kisspeptin peptide guide: reproductive hormone signaling and telehealth questions
A clear guide for kisspeptin readers, focused on hormonal context, labs, and state-aware prescribing.
PT-141 vs ED medications: what telehealth patients need to compare
A high-intent comparison between desire-focused and erection-focused medication categories.
Sexual-health peptide telehealth checklist: PT-141, oxytocin, kisspeptin, and labs
A patient-facing checklist for evaluating sexual-health peptide programs and follow-up support.
Women’s and men’s sexual-health telehealth: how peptide care pathways needs to be explained
A patient-facing reference that separates indications, assessment, contraindications, and follow-up by care pathway.
Clinical evidence and access data
This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.
| Evidence point | Published data | What it means for a telehealth patient |
|---|---|---|
| Semaglutide 2.4 mg, STEP 1 | Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo. | Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility. |
| Tirzepatide, SURMOUNT-1 | Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo. | Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing. |
| Compounded GLP-1 status | FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. | Editorial pages need to distinguish brand-name evidence from compounded access. |
| State access | Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping. | Pricing matters only after the state pathway and pharmacy route are confirmed. |
Trial outcome chart
Sources
- STEP 1 semaglutide trial
- SURMOUNT-1 tirzepatide trial
- FDA: concerns with unapproved GLP-1 drugs used for weight loss
- CCHP state telehealth policy finder
Compare NexLife GLP-1 pricing
Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.